The NETest The Clinical Utility of Multigene Blood Analysis - in the Diagnosis and Management of Neuroendocrine Tumors

被引：105

作者：

Modlin, Irvin M. ^{[1
]}

Kidd, Mark ^{[2
]}

Malczewska, Anna ^{[3
]}

Drozdov, Ignat ^{[2
]}

Bodei, Lisa ^{[4
]}

Matar, Sourer ^{[2
]}

Chung, Kyung-Min ^{[2
]}

机构：

[1] Yale Univ, Sch Med, Gastroenterol & Endoscop Surg, 310 Cedar St, New Haven, CT 06520 USA

[2] Wren Labs, 35 NE Ind Rd, Branford, CT 06405 USA

[3] Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Ul Ceglana 35, PL-40514 Katowice, Poland

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave,Box 77, New York, NY 10065 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2018年 / 47卷 / 03期

关键词：

NETest; Multigene blood analysis; Neuroendocrine tumors; Peptide receptor radionuclide therapy; Bronchopulomary carcinoid; Transcript; Progression; PCR; Blood; Biomarker; POLYMERASE CHAIN-REACTION; CHROMOGRANIN-A; TRANSCRIPT ANALYSIS; HEPATIC METASTASES; PROGNOSTIC-FACTORS; LIQUID BIOPSIES; LUNG-CANCER; HALLMARKS; EXPRESSION; SURVIVAL;

D O I：

10.1016/j.ecl.2018.05.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold more accurate than chromogranin A. NETest accurately identifies completeness of surgery and response to somatostatin analogs. Clinical registry data demonstrate significant clinical utility in watch/wait programs.

引用

页码：485 / +

页数：22

共 81 条

[1] Appendiceal neuroendocrine neoplasms: diagnosis and management [J].

Alexandraki, Krystallenia I. ;

Kaltsas, Gregory A. ;

Grozinsky-Glasberg, Simona ;

Chatzellis, Eleftherios ;

Grossman, Ashley B. .

[2]

Alvarez M.J., Nat Genet

[3]

[Anonymous], NEUROENDOCRINOLOGY

[4]

[Anonymous], CURR OPIN ENDOCRINOL

[5]

[Anonymous], 2017, ONCOTARGET

[6] The Evolving Landscape of Neuroendocrine Tumors [J].

Bergsand, Emily K. .

SEMINARS IN ONCOLOGY, 2013, 40 (01) :4-22

[7] 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors [J].

Binderup, Tina ;

Knigge, Ulrich ;

Loft, Annika ;

Federspiel, Birgitte ;

Kjaer, Andreas .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :978-985

[8] Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors [J].

Bodei, L. ;

Kidd, M. ;

Modlin, I. M. ;

Severi, S. ;

Drozdov, I. ;

Nicolini, S. ;

Kwekkeboom, D. J. ;

Krenning, E. P. ;

Baum, R. P. ;

Paganelli, G. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (05) :839-851

[9]

Bodei L, 2014, ENETS C BARC SPAIN M

[10] PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy [J].

Bodei, Lisa ;

Kidd, Mark S. ;

Singh, Aviral ;

van der Zwan, Wouter A. ;

Severi, Stefano ;

Drozdov, Ignat A. ;

Cwikla, Jaroslaw ;

Baum, Richard P. ;

Kwekkeboom, Dik J. ;

Paganelli, Giovanni ;

Krenning, Eric P. ;

Modlin, Irvin M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (07) :1155-1169

← 1 2 3 4 5 6 7 8 9 →